Literature DB >> 16941575

Management of Kell isoimmunization--evaluation of a Doppler-guided approach.

E Rimon1, R Peltz, R Gamzu, S Yagel, B Feldman, B Chayen, R Achiron, S Lipitz.   

Abstract

OBJECTIVE: To assess the role of peak systolic velocity in the middle cerebral artery (MCA-PSV) in the management of pregnancies complicated by Kell isoimmunization.
METHODS: Sixteen fetuses were monitored by conventional protocol (Group 1) and eight fetuses by an MCA-PSV-guided protocol (Group 2). The conventional protocol included a weekly ultrasound evaluation and measurement of maternal anti-Kell titers every 4-6 weeks. In Group 2 Doppler assessment of the MCA-PSV was performed at intervals of 4 to 7 days and MCA-PSV>1.5 multiples of the median (MoM) was considered as an indication for fetal blood sampling (FBS).
RESULTS: No parameter emerged as a reliable predictor of isoimmunization severity in Group 1. In Group 2, no FBS was necessary in one case since the MCA-PSV values obtained during the follow-up were <1.29 MoM. In two cases the first FBS was already indicated after 1 week of follow-up, but five other fetuses were followed for 3-9 weeks before FBS was indicated. All fetuses with MCA-PSV>1.5 MoM prior to intrauterine transfusion (IUT) had severe fetal anemia on FBS. In fetuses with severe anemia on the first FBS, the MCA-PSV values 7 days before the first FBS were <1.29 MoM (four cases), between 1.29 and 1.5 MoM (two cases) and >1.55 MoM (one case).
CONCLUSIONS: In the management of Kell isoimmunization invasive procedures may be avoided by implementing MCA-PSV measurements. Delineation of appropriate intervals between reassessments, the reliability of MCA-PSV following repeated IUTs, and cut-off values for FBS await further study. Copyright (c) 2006 ISUOG.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16941575     DOI: 10.1002/uog.2837

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

1.  Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies.

Authors:  Sean R Stowell; Kathryn R Girard-Pierce; Nicole H Smith; Kate L Henry; C Maridith Arthur; James C Zimring; Jeanne E Hendrickson
Journal:  Transfusion       Date:  2013-04-29       Impact factor: 3.157

2.  Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model.

Authors:  Sean R Stowell; Kate L Henry; Nicole H Smith; Krystalyn E Hudson; Greg R Halverson; Jaekeun C Park; Ashley M Bennett; Kathryn R Girard-Pierce; C Maridith Arthur; Silvia T Bunting; James C Zimring; Jeanne E Hendrickson
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

3.  Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Satheesh Chonat; Andreas Wieland; Manjula Santhanakrishnan; Jingchun Liu; Cheryl L Maier; Ryan P Jajosky; Kathryn Girard-Pierce; Ashley Bennett; Patricia E Zerra; Nicole H Smith; Jeanne E Hendrickson; Sean R Stowell
Journal:  JCI Insight       Date:  2018-11-15

4.  Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Authors:  Seema R Patel; David R Gibb; Kathryn Girard-Pierce; Xiaoxi Zhou; Lilian Cataldi Rodrigues; Connie M Arthur; Ashley L Bennett; Ryan P Jajosky; Megan Fuller; Cheryl L Maier; Patricia E Zerra; Satheesh Chonat; Nicole H Smith; Christopher A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

5.  Hydrops Fetalis due to Kell Alloimmunization: A Perinatal Approach to a Rare Case.

Authors:  Arzu Akdağ; Omer Erdeve; Nurdan Uraş; Yavuz Simşek; Uğur Dilmen
Journal:  Turk J Haematol       Date:  2012-03-05       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.